Literature DB >> 20221868

Paraoxonase 1 status as a risk factor for disease or exposure.

Rebecca J Richter1, Gail P Jarvik, Clement E Furlong.   

Abstract

Human paraoxonase 1 (PON1) has broad substrate specificity and has been shown to protect against exposure to some organophosphorus (OP) insecticides due to its ability to hydrolyze toxic metabolites of some organophosphorothioate insecticides. PON1 status has been shown to be important in protecting against vascular disease, presumably due to the not-as-yet fully characterized role of the three PON proteins in modulating oxidative stress. More recently, all three PONs (1, 2, and 3) have been shown to inactivate the quorum sensing factor N-(3-oxododecanoyl)-L: -homoserine lactone (3OC12-HSL) of Pseudomonas. Expression of human PON1 in Drosophila demonstrated the importance of PON1 in resistance to Pseudomonas infection. Many studies have examined only DNA single nucleotide polymorphisms as possible risk factors for disease or exposures. For all of the known functions of PON1, the level of PON1 enzyme is important and, in some cases, also the Q192R polymorphism. A simple high throughput two-substrate assay/analysis, plotting rates of diazoxon hydrolysis vs. paraoxon hydrolysis, provided both PON1 levels and functional Q192R phenotype/genotype. We have developed a new two-substrate assay/analysis protocol that provides PON1 status without use of toxic OP substrates. Factors were determined for inter-converting rates of hydrolysis of different substrates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20221868      PMCID: PMC2868909          DOI: 10.1007/978-1-60761-350-3_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  23 in total

1.  Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease.

Authors:  Bert N La Du
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-08-01       Impact factor: 8.311

2.  Determination of paraoxonase (PON1) status requires more than genotyping.

Authors:  R J Richter; C E Furlong
Journal:  Pharmacogenetics       Date:  1999-12

3.  Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?

Authors:  B Mackness; G K Davies; W Turkie; E Lee; D H Roberts; E Hill; C Roberts; P N Durrington; M I Mackness
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-09       Impact factor: 8.311

4.  The human serum paraoxonase/arylesterase polymorphism.

Authors:  H W Eckerson; C M Wyte; B N La Du
Journal:  Am J Hum Genet       Date:  1983-11       Impact factor: 11.025

5.  Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds.

Authors:  W F Li; L G Costa; R J Richter; T Hagen; D M Shih; A Tward; A J Lusis; C E Furlong
Journal:  Pharmacogenetics       Date:  2000-12

6.  Inactivation of a Pseudomonas aeruginosa quorum-sensing signal by human airway epithelia.

Authors:  Carlene K Chun; Egon A Ozer; Michael J Welsh; Joseph Zabner; E P Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

7.  Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status.

Authors:  Gail P Jarvik; Rachel Jampsa; Rebecca J Richter; Chris S Carlson; Mark J Rieder; Deborah A Nickerson; Clement E Furlong
Journal:  Pharmacogenetics       Date:  2003-05

Review 8.  Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1.

Authors:  Sara P Deakin; Richard W James
Journal:  Clin Sci (Lond)       Date:  2004-11       Impact factor: 6.124

9.  Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor.

Authors:  Sara Deakin; Ilia Leviev; Marie-Claude Brulhart-Meynet; Richard W James
Journal:  Biochem J       Date:  2003-06-01       Impact factor: 3.857

10.  Determination of paraoxonase 1 status without the use of toxic organophosphate substrates.

Authors:  Rebecca J Richter; Gail P Jarvik; Clement E Furlong
Journal:  Circ Cardiovasc Genet       Date:  2008-12
View more
  21 in total

1.  Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme.

Authors:  Priyanka Bajaj; Rajan K Tripathy; Geetika Aggarwal; Abhay H Pande
Journal:  Protein Sci       Date:  2013-10-26       Impact factor: 6.725

2.  Dietary cholesterol increases paraoxonase 1 enzyme activity.

Authors:  Daniel S Kim; Amber A Burt; Jane E Ranchalis; Rebecca J Richter; Julieann K Marshall; Karen S Nakayama; Ella R Jarvik; Jason F Eintracht; Elisabeth A Rosenthal; Clement E Furlong; Gail P Jarvik
Journal:  J Lipid Res       Date:  2012-08-15       Impact factor: 5.922

3.  Serum Paraoxonase (PON1) Activity in North-West Indian Punjabi's with Acute Myocardial Infarction.

Authors:  V Nagarjuna Maturu; Nidhi Gupta; Gagandip Singh; Kirandip Gill; Yash Paul Sharma; Surjit Singh
Journal:  Indian J Clin Biochem       Date:  2012-10-11

4.  Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity.

Authors:  Chiara Cristina Bortolasci; Heber Odebrecht Vargas; André Souza-Nogueira; Estefania Gastaldello Moreira; Sandra Odebrecht Vargas Nunes; Michael Berk; Seetal Dodd; Décio Sabbatini Barbosa; Michael Maes
Journal:  Redox Rep       Date:  2014-07-18       Impact factor: 4.412

5.  Preliminary study on serum paraoxonase-1 status and chemokine (C-C motif) ligand 2 in hospitalized elderly patients with catheter-associated asymptomatic bacteriuria.

Authors:  S Iftimie; A García-Heredia; I Pujol; F Ballester; I Fort-Gallifa; J M Simó; J Joven; J Camps; A Castro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-22       Impact factor: 3.267

Review 6.  Paraoxonase 1 in neurological disorders.

Authors:  Teresita Menini; Alejandro Gugliucci
Journal:  Redox Rep       Date:  2013-11-12       Impact factor: 4.412

7.  Effect of propolis and N-acetylcysteine supplementation on lipoprotein subclasses distribution and paraoxonase 1 activity in subjects with acute respiratory infection.

Authors:  Jelena Vekić; Jasmina Ivanišević; Aleksandra Zeljković; Vesna Spasojević-Kalimanovska; Nataša Bogavac-Stanojević; Marija Mihajlović; Jelena Janać; Sanja Vujčić; Milica Miljković; Dejan Zujović; Jelena Kotur-Stevuljević
Journal:  J Med Biochem       Date:  2020-10-02       Impact factor: 3.402

8.  Salt overload in fructose-fed insulin-resistant rats decreases paraoxonase-1 activity.

Authors:  Waleska Cláudia Dornas; Wanderson Geraldo de Lima; Rinaldo Cardoso Dos Santos; Melina Oliveira de Souza; Maísa Silva; Mirla Fiuza Diniz; Marcelo Eustáquio Silva
Journal:  Nutr Metab (Lond)       Date:  2012-06-27       Impact factor: 4.169

9.  Associations of PON1 and genetic ancestry with obesity in early childhood.

Authors:  Karen Huen; Kim Harley; Kenneth Beckman; Brenda Eskenazi; Nina Holland
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

10.  PON1 and neurodevelopment in children from the CHAMACOS study exposed to organophosphate pesticides in utero.

Authors:  Brenda Eskenazi; Karen Huen; Amy Marks; Kim G Harley; Asa Bradman; Dana Boyd Barr; Nina Holland
Journal:  Environ Health Perspect       Date:  2010-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.